A Multicenter, Multinational, Open-Label, Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)
Phase of Trial: Phase I/II
Latest Information Update: 05 Feb 2018
At a glance
- Drugs Elosulfase alfa (Primary)
- Indications Mucopolysaccharidosis IV
- Focus Adverse reactions; Therapeutic Use
- Sponsors BioMarin Pharmaceutical
- 05 Feb 2018 According to a BioMarin Pharmaceutical media release, data will be presented at the 14th Annual WORLDSymposiumTM 2018.
- 24 Sep 2014 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 16 May 2014 EudraCT reports trial status as recruiting.